anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. ^ SUBSTANCE: disclosed is a plasmid for producing a viral vector transporting multiple expression cassettes to a target. The plasmid contains genome nucleotide sequences packed into a polyvalent capsid and a number of cassettes to be transported. A method for producing a viral vector, a viral vector and an immunogenic composition are described besides. ^ EFFECT: group of inventions can be used for wide-ranging expression of target antigens. ^ 23 cl, 3 dwg
This relates to the pharmaceutical use of KOH, in forms of topical, oral drugs or intravenous drip, prepared for treating high blood uric acid, especially gout. The external application refers to footbath in soaking solution or embrocation on attack position. The action of the drugs is also to promote the excretion of uric acid. Compared with colchicine and other drugs, KOH has three notable features. First, it takes effect quickly. No matter being applied by footbath, oral or embrocation, it can relieve symptoms within ten minutes, and the pain during gout attack will be significantly reduced. Second, it takes curative effect quickly. After application of the drugs for 2-3 consecutive days, gout symptoms will completely disappear. Third, it has no side effects. In one respect, with a low concentration, the KOH will not corrode the skin. In a further respect, potassium ion itself is diuretic and it has no harm to kidney.
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy and liver transplantation are considered to be standard curative therapies for HCC. When surgery is not possible, percutaneous ablation is usually considered to be alternative treatments for HCC . Recurrence is the most frequent serious adverse event observed during the follow-up of HCC patients treated for cure. Repeat hepatectomy is an effective treatment for HCC recurrence, with a 5-year survival rate of 19.4 to 56%. Unfortunately, repeat hepatectomy can be performed only in a small proportion of patients with HCC recurrence (10.4 to 31%), either because of the poor functional liver reserve or because of widespread recurrence.(15, 17, 18) Radiofrequency ablation (RFA) has been considered to be one of the most effective percutaneous ablations for early-stage HCC in patients with or without surgical prospects . Studies using RFA to treat HCC recurrence after hepatectomy have reported a 3-year survival rate of 62% to 68%, which is comparable to those achieved by surgery. RFA is particularly suitable to treat HCC recurrence after hepatectomy because these tumors are usually detected when they are small, and because RFA causes the least deterioration of liver function in the patients. RFA is also effective for managing HCC recurrence after initial treatment of RFA. Clinical data have shown that, after repeated RFA, the estimated 3-and 5-year overall, and disease-free survival rates for patients with HCC recurrence were 67.0% and 40.1% and 68.0 and 38.0%, respectively.Therefore, we considered RFA to be an effective treatment for HCC recurrence after curative treatment.

The combination of transcatheter arterial chemoembolization (TACE) with RFA has also reported to be an effective treatment for HCC. Studies have shown TACE combined RFA to have better efficacy than RFA for medium-sized HCC (3-5 cm) and multiple-tumor HCC, but not for small HCC (≤3 cm). However, to our knowledge, there have not been any prospective studies to assess whether TACE combined sequentially with RFA is more effective than RFA alone for the treatment of HCC recurrence after curative treatment. We hypothesized that the combination of TACE and RFA might result in better patient survival than RFA alone. Thus, the purpose of this study was to prospectively compare the effects of sequential TACE-RFA with RFA alone for the treatment of recurrent HCC. Recurrent HCC in this study was defined as new tumors in the remnant liver, distant from the resection or ablation site after curative treatment of RFA or hepatectomy.
1. A method of reducing tooth erosion caused by acid in orally administered compositions comprising orally administering a solid or semi-solid composition comprising a calcium compound and an acidulant, wherein calcium is present in the range of 0.3 to 0.65 mol per mol of acid and the amount of calcium and acidulant in the composition is selected so that the effective pH of the composition is from 3.5 to 4.5. 2. A method as claimed in claim 1 in which the calcium is present in the range 0.3-0.55 mol per mol of acid. 3. A method as claimed in any of claims 1 or 2 in which the calcium is present in an amount of at least 0.4 mol per mol of acid. 4. A method as claimed in any of claims 1 to 3 in which the effective pH of the composition is not more than 4. 5. A method as claimed in any of claims 1 to 4 in which the effective pH is from 3.7 to 3.9. 6. A composition as claimed in any one of claims 1 to 5 in which the acid is citric acid, malic acid or lactic acid or mixtures thereof. 7. A composition as claimed in any one of claims 1 to 6 in which the calcium compound is calcium carbonate, calcium hydroxide, calcium citrate, calcium malate, calcium lactate, calcium chloride, calcium glycerophosphate or calcium formate. 8. A composition as claimed in any one of claims 1 to 7 which is a sweet. 9. A composition as claimed in claim 8 in which the sweet is a pastille. 10. A composition as claimed in any one of claims 1 to 9 which is an oral healthcare composition. 11. Use of a solid or semi-solid composition comprising a calcium compound and an acidulant wherein calcium is present in the composition in the range of 0.3 to 0.8 mol per mol of acid and the amount of calcium and acidulant in the composition is selected so that the effective pH of the composition is from 3.5 to 4.5 in the manufacture of an orally administered composition for the reduction of tooth erosion caused by acid,. 12. Use as claimed in claim 11 in which the calcium is present in the range 0.3 -0.75 mol per mol of acid. 13. Use as claimed in any one of claims 11 or 12 in which the effective pH of the composition is not more than 4. 14. Use as claimed in any one of claims 11 to 13 in which the effective pH is from 3.7 to 3.9. 15. A process for preparing a solid or semi-solid composition containing a calcium compound and an acidulant characterised in that calcium is present in the range 0.3 to 0.8 mol per mol of acid and the effective pH of the composition is from 3.5 to 4.5, comprising mixing the calcium compound with the acidulant so that calcium is present in the range of 0.3 to 0.65 mol per mol of acid, and adjusting the pH, if necessary or desired, by addition of alkali so that the effective pH of the composition is in the range 3.5 to 4.5.
PROBLEM TO BE SOLVED: To obtain the subject gel having salt tolerance, capable of containing an inorganic salt in a high concentration and freely adjusting viscoelasticity thereof to give a high adhesiveness to the skin, capable of containing a functional component and a component with drug action and useful for cosmetic or the like for prevention of skin aging and chapped skin by including carrageenan as a gelling component, a functional component such as tourmaline fine powder and trehalose. SOLUTION: (A) A suitable amount of water is added to carrageenan which is extracted from a seaweed as a gelling component, and (B) an alkali metal ion such as potassium ion or cesium ion is included, and (C) a functional component such as a deep sea water containing a natural mineral component, a functional water made by electrolysis and/or tourmaline fine powder, an oil and fat of plant (ex. borage oil, evening primrose oil, avocado oil, etc.), an alcohol, an extract from plants or bacteria (ex. a Panax ginseng extract, a swertia herb extract, a yeast extract, a bifidobacterium extract, etc.), and (D) trehalose are included.
A method for the accumulation of trace-labeled or therapeutic insoluble molecules in targeted cells of a living host for purposes including diagnosis, therapy, and research in cell biology. The method enables soluble precipitable materials, which can be trace-labeled or therapeutic, to be made to accumulate as non-digestible precipitates in targeted cells as a result of enzyme action within the targeted cells. Accumulation is achieved by administering to the living host a soluble binary reagent having a targeting agent attached to a chemical agent which is a soluble precipitable material. The binary reagent binds to antigenic receptors on targeted cells which endocytosed the binary reagent and transport it into the lysosomes where enzymes detach the soluble precipitable material from the targeting agent, causing it to precipitate, accumulate, and be retained in the cells. Continuing the administration of the binary reagent forms an accumulation of precipitate which becomes a stable insoluble tracer agent or a stable insoluble therapeutic agent in the targeted cells. The method can be applied to the diagnosis and scanning of certain diseased states, and to the therapy of certain diseased states, such as cancer, by generating supra-lethal micro-regions of radiation around targeted cells called Hot-Spots which are capable of killing, non-specifically, all cells in the immediate micro-region.
In one aspect, a computerized method for optimizing medication processing, dispensing and delivery using opportunistic refill opportunities in a geographic region in an automated medication refill system includes the step of obtaining an ordinary refill queue for a set of customers for a specified current time period. The ordinary refill queue comprises a list of medications to be automatically filled and delivered during the specified current time period. The method includes the step of determining a delivery location for each customer in the ordinary prescription refill queue of an automated medication refill system. The method includes the step of identifying a geographic region that includes each customer in the ordinary medication refill queue. The method includes the step of identifying a set of opportunistic refill customers in the geographic region, wherein an opportunistic refill opportunity comprises a future medication refill that is set to be refilled in a specified future time period. The method includes the step of determining a delivery location for each opportunistic refill customer that is in the geographic region. The method includes the step of changing the status of the refill processing and dispensing from the specified future time period to the specified current time period. The method includes the step of determining an optimized processing, dispensing and route for delivery of the medications to each customer in the ordinary refill queue to each opportunistic refill customers in the geographic region.
BACKGROUND: Artemisinin-based combination therapy (ACT) has been effective in the supervised treatment of uncomplicated malaria in Ghana. Since ACT usage is primarily unsupervised, this study aimed to determine the effectiveness of artemether-lumefantrine (AL) for treating malaria patients in two transmission settings in Ghana.
METHODS: Eighty-four individuals with uncomplicated Plasmodium falciparum malaria were recruited from Lekma Hospital (LH) in Accra (low-transmission area; N = 28), southern Ghana, and King's Medical Centre (KMC) in Kumbungu (high-transmission area; N = 56), northern Ghana. Participants were followed up for 28 days after unsupervised treatment with AL. The presence of asexual parasites was determined by microscopic examination of Giemsa-stained blood smears. Plasmodium species identification was confirmed using species-specific primers targeting the 18S rRNA gene. Parasite recrudescence or reinfection was determined by genotyping the Pfmsp 1 and Pfmsp 2 genes.
RESULTS: After AL treatment, 3.6% (2/56) of the patients from KMC were parasitaemic on day 3 compared to none from the LH patients. One patient from KMC with delayed parasite clearance on day 3 remained parasite-positive by microscopy on day 7 but was parasite-free by day 14. While none of the patients from LH experienced parasite recurrence during the 28-day follow-up, three and two patients from KMC had recurrent parasitaemia on days 21 and 28, respectively. Percentage reduction in parasite densities from day 1, 2, and 3 for participants from the KMC was 63.2%, 89.5%, and 84.5%. Parasite densities for participants from the LH reduced from 98.2%, 99.8% on day 1, and 2 to 100% on day 3. The 28-day cumulative incidence rate of treatment failure for KMC was 12.8% (95% confidence interval: 1.9-23.7%), while the per-protocol effectiveness of AL in KMC was 89.47%. All recurrent cases were assigned to recrudescence after parasite genotyping by Pfmsp 1 and Pfmsp 2.
CONCLUSION: While AL is efficacious in treating uncomplicated malaria in Ghana, when taken under unsupervised conditions, it showed an 89.4% PCR-corrected cure rate in northern Ghana, which is slightly below the WHO-defined threshold.
Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. As in any case of overdose, general supportive measures should be utilized.

  
As rivastigmine has a plasma half-life of about 3.4 hours after patch administration and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose the patch should be immediately removed and no further patch should be applied for the next 24 hours.

As in any case of overdose, general supportive measures should be utilized. Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when coadministered with quaternary anticholinergics such as glycopyrrolate. Due to the short plasma elimination half-life of rivastigmine after patch administration, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an overdose.

In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. In a documented case of an oral 46-mg overdose with Exelon, the patient experienced vomiting, incontinence, hypertension, psychomotor retardation, and loss of consciousness. The patient fully recovered within 24 hours and conservative management was all that was required for treatment.

There are currently no data on overdose with Exelon Patch (rivastigmine transdermal system).
Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
ABSTRACT    An allantoin ascorbic acid complex is disclosed as in an allantoin salt ascorbic acid complex.  Medicinal and cosmetic compositions containing these complexes are also disclosed.  More particularly, the invention is a complex of allantoin and ascorbic acid selected from the group consisting of an allantoin ascorbic acid complex having the formula [C4M5N4O3]x ? [C5H8O6]y ; an aluminum chlorhydroxy allantoinate ascorbic acid complex having the formula [Al2(OH)3ClC4H4N4O3] ? [C5H7O6]y ; and an aluminum hydroxy allanoinate ascorbic acid complex having the formula [A1(OH)C2H4N4O3]x ? [C5H7O6]y ; wherein x and y are each approximately unity.
Pregnancy Category C  
There are no adequate and well-controlled studies in pregnant women. OraVerse should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Oral administration of phentolamine to pregnant rats and mice at doses at least 24 times the recommended dose (based on a 60 kg human) resulted in slightly decreased growth and slight skeletal immaturity of the fetuses. Immaturity was manifested by increased incidence of incomplete or unossified calcaneal and phalangeal nuclei of the hind limb and of incompletely ossified sternebrae. At oral phentolamine doses at least 60 times the recommended dose (based on a 60 kg human), a slightly lower rate of implantation was found in the rat. Phentolamine did not affect embryonic or fetal development in the rabbit at oral doses at least 20 times the recommended dose (based on a 60 kg human). No teratogenic or embryotoxic effects were observed in the rat, mouse, or rabbit studies.
We conducted a monocentric randomized controlled trial starting from Mars 2017, recruitment is still ongoing. Patients aged between 0-45 days needing mechanical ventilation (MV) with tracheal intubation were included regardless type of admission, severity of disease and randomly assigned in two groups for post-extubation management: Group Optiflow (GO) for patients receiving HNFC oxygen therapy and Control Group (CG) for conventional treatment. Before programmed extubation, newborns and young infants received 0.15 mg/kg of Dexamethasone. Patients were evaluated during the first 72h following extubation. Primary endpoint was the incidence of reintubation. Secondary endpoints were incidence of post-extubation respiratory failure, time to reintubate and weaning time from oxygen. Respiratory and hemodynamic parameters were assessed and compared between the two groups upon extubation, after 2 hours (H2), at H6, H12, H24, H36, H48 and H72. Length of stay (LOS) and mortality were also estimated.
The app will be implemented with the participant's compatible iPad that will be securely integrated with a network-server for real-time data access and storage. If the participant does not have a compatible device, this will be provided by the research team. Participants will be provided an on-site or virtual CHLA tutorial about using the app and set up of the gaming system. Participants will access their home program on the app at least for 20 minutes, 3 times a week over a 4-week period. A coordinator will check in virtually with the participant during the program. They will complete baseline and final surveys. Exercise data will be collected and stored through the Augment Therapy™ app and self log book.
Currently, the typical combination therapy of programmed death ligand-1 (PD-L1) antibodies with radiotherapy (RT) still exhibits impaired immunogenic antitumor response in clinical due to lessened DNA damage and acquired immune tolerance via the upregulation of some other immune checkpoint inhibitors. Apart from this, such combination therapy may raise the occurrence rate of radiation-induced lung fibrosis (RIPF) due to enhanced systemic inflammation, leading to the ultimate death of cancer patients (average survival time of about 3 years). Therefore, it is newly revealed that mitochondria energy metabolism regulation can be used as a novel effective PD-L1 and transforming growth factor-β (TGF-β) dual-downregulation method. Following this, IR-TAM is prepared by conjugating mitochondria-targeted heptamethine cyanine dye IR-68 with oxidative phosphorylation (OXPHOS) inhibitor Tamoxifen (TAM), which then self-assembled with albumin (Alb) to form IR-TAM@Alb nanoparticles. By doing this, tumor-targeting IR-TAM@Alb nanoparticle effectively reversed tumor hypoxia and depressed PD-L1 and TGF-β expression to sensitize RT. Meanwhile, due to the capacity of heptamethine cyanine dye in targeting RIPF and the function of TAM in depressing TGF-β, IR-TAM@Alb also ameliorated fibrosis development induced by RT.
Anxiety and fear are key characteristics of eating disorders (EDs). Exposure therapy is a specific type of intervention aimed at reducing fear and anxiety and is efficacious in treating a variety of anxiety and related disorders. A growing body of research suggests that exposure therapy is also efficacious for the treatment of EDs. However, there is currently little research investigating mechanisms of change during exposure therapy for EDs. The current study (N = 143) expanded on an open series trial of imaginal exposure for EDs that found significant reductions in ED symptoms and core ED fears. In the current study we investigated change in state drive for thinness, body dissatisfaction, and anxiety as mechanisms underpinning change in ED symptoms and core ED fears during four sessions of online imaginal exposure treatment for EDs. We found that state body dissatisfaction, but not state drive for thinness or anxiety, was a mechanism of change for ED symptoms and some core ED fears. Our findings suggest that body dissatisfaction may be a mechanism driving change during exposure therapy for EDs. Optimizing exposure treatments to focus on body dissatisfaction may improve treatment outcomes for EDs.
Fusarium wilt (FW) is widespread in global cotton production, but the mechanism underlying FW resistance in superior-fiber-quality Sea Island cotton is unclear. This study reveals that FW resistance has been the target of genetic improvement of Sea Island cotton in China since the 2010s. The key nonsynonymous single nucleotide polymorphism (SNP, T/C) of gene Gbar_D03G001670 encoding protein phosphatase 2C 80 (PP2C80) results in an amino acid shift (L/S), which is significantly associated with FW resistance of Sea Island cotton. Silencing GbPP2C80 increases FW resistance in Sea Island cotton, whereas overexpressing GbPP2C80 reduces FW resistance in Arabidopsis. GbPP2C80 and GbWAKL14 exist synergistically in Sea Island cotton accessions with haplotype forms "susceptible-susceptible" (TA) and "resistant-resistant" (CC), and interact with each other. CRISPR/Cas9-mediated knockout of GbWAKL14 enhances FW and Verticillium wilt (VW) resistance in upland cotton and overexpression of GbWAKL14 and GbPP2C80 weakens FW and VW resistance in Arabidopsis. GbPP2C80 and GbWAKL14 respond to FW and VW by modulating reactive oxygen species (ROS) content via affecting MPK3 expression. In summary, two tandem genes on chromosome D03, GbPP2C80, and GbWAKL14, functions as cooperative negative regulators in cotton wilt disease defense, providing novel genetic resources and molecular markers for the development of resistant cotton cultivars.
Cell isomeric state is an energy state which is used for identifying a cell by way of peak and mass of an ultraviolet spectrum absorbed by a cell structure. DNA and proteins are combined to form a gene, which is one of important properties of nucleus. The binding energy of nucleus is the measure of genomic stability. The greater the specific binding energy is, the more stable the nucleus is. As far as highly excited level of cancer (cell heterogeneity) isotope as concerned, tumor suppressor gene-cell isomer is a substance in a lowly excited level. The main ideal of biological isomer tumor suppression is dependent on cell isotope equilibrium principle. By means of balanced exchange of cancer isotope in the highly excited level by an isomer substance in the lowly excited level, the purpose of fundamentally treating carcinoma is achieved. The substances in the lowly excited level of a homogeneous cancer cell are prepared by a DNA time machine. According to the tumor suppressor gene-cell isomer, oncogene quantization and immobility of binding energy are thoroughly eradicated by means of mixed and balanced repair by virtue of cancer suppressor genes and cancer cells. The establishment of tumor suppressor gene-cell isomer marks approach of the biological isotope application century.